Therapeutic effect of telbivudine combined with Fuzheng Huayu tablets in treatment of liver fibrosis in chronic hepatitis B: a report of 60 cases

Linchuang Gandanbing Zazhi

卷:29

关键词: telbivudine;    FUZHENG HUAYU TABLET;    hepatitis B;    chronic;    livercirrhosis;   

DOI  :  10.3969/j.issn.1001-5256.2013.09.014

来源: DOAJ

【 摘 要 】

ObjectiveTo investigate the therapeutic effect of telbivudine combined with Fuzheng Huayu tablets in the treatment of liver fibrosis in chronic hepatitis B (CHB). MethodsA total of 120 patients with CHB, who were admitted to our hospital from July 2011 to November 2012, were randomly divided into treatment group (n=60) and control group (n=60). All patients received antiviral and liver-protecting therapy with telbivudine; meanwhile, the treatment group was given Fuzheng Huayu tablets as an addition for 6 months. The liver function, four indices for liver fibrosis, and patient′s symptoms and signs were evaluated. The enumeration data were analyzed by chi-square test, and the measurement data were analyzed by t-test. ResultsAfter 6 months of treatment, the treatment group showed normalized aspartate aminotransferase (AST), albumin/globulin ratio (A/G), and total bilirubin (TBil) as well as decreased alanine aminotransferase (ALT), and there were significant differences between the treatment group and control group in AST (33.1±15.5 vs 39.5±18.4, t=2.060, P＜0.05), A/G (1.78±0.41 vs 1.64±0.32, t=2.085, P＜0.05), TBil (13.8±6.6 vs 17.9±8.3, t=3.172, P＜005), and ALT (55.3±23.4 vs 64.7±27.6, t=2.012, P＜005); also, the treatment group showed significant improvements in hyaluronic acid (HA), laminin (LN), type Ⅲ procollagen peptide (PⅢP), and type Ⅳ collagen (Ⅳ-C), and there were significant differences between the treatment group and control group in HA (1077±82.3 vs 141.6±91.4, t=2.155, P＜0.05), LN (125.4±73.2 vs 154.9±76.5, t=2.135, P＜0.05), PⅢP (0.61±0.56 vs 096±0.44, t=3.266, P＜0.05), and IV-C (90.6±78.3 vs 134.3±67.9, t=3.807, P＜0.05). In addition, the treatment group had alleviated lassitude, improved appetite, and palliated abdominal distension, demonstrating significant differences compared with the control group (71.7% vs 53.3%, P＜0.05; 83.3% vs 65.0%, P＜0.05; 80.0% vs 58.3%, P＜0.05). ConclusionWhen used along with Fuzheng Huayu tablets, telbivudine has better performances in relieving symptoms, improving liver function, and reducing liver fibrosis in CHB patients with liver fibrosis.

【 授权许可】

Unknown